echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Cell Res: Peng Xiaozhong/Deng Hongkui has proposed a new strategy for treating new coronary pneumonia, targeting macrophages.

    Cell Res: Peng Xiaozhong/Deng Hongkui has proposed a new strategy for treating new coronary pneumonia, targeting macrophages.

    • Last Update: 2020-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Due to the rapid increase in new cases, coronavirus disease (COVID-19) in 2019 quickly attracted global attention and the pathogen was identified as SARS-CoV-2.
    these figures are updated daily and are expected to increase further.
    autopsy found that macrophages were strongly immersed in the lung tissue of patients with the deadly COVID-19.
    addition, single-cell RNA sequencing (scRNA-seq) showed a higher proportion of macrophages in bronchid alfalfa sequencing (BALF) in patients with severe COVID-19.
    , regulating excessive inflammation in SARS-CoV-2 infections for macrophages may be an effective strategy for treating PATIENT-19 patients.
    September 30, 2020, Peng Xiaozhong of the Concord Medical College of Beijing and Deng Hongkui of Peking University published a research paper entitled "Effective treatment of SARS-CoV-2-infected rhesus macaques by attenuating inflammation" published online by Cell Research, which demonstrated that the small molecule SSK1 effectively treats COVID-19 pneumonia by controlling macrophage immersion.
    SSK1 effectively alleviated clinical symptoms, reduced the pathological pneumonia of SARS-CoV-2 infection, and reduced macrophage immersion in lungs in animals treated with SSK1.
    results show that SSK1 has broad therapeutic potential in the treatment of pneumonia and excessive inflammation of SARS-CoV-2 infection.
    the study also found that SSK1 reduced cytokine levels in the extraterroral blood of older monkeys.
    , targeting macrophages through SSK1 may be a promising strategy for controlling inflammation in COVID-19 therapy.
    2019 coronavirus disease (COVID-19) quickly attracted global attention due to the rapid increase in new cases.
    new coronavirus infection is believed to have been transmitted from animals, and pathogens have been identified as SARS-CoV-2.
    until January 2020, it is suspected that the first infected patients were infected with the virus through human-to-human transmission.
    since January 2020, the virus has spread rapidly to most of China and other countries.
    the rapid increase in new cases, coronavirus disease (COVID-19) in 2019 quickly attracted global attention, with pathogens identified as SARS-CoV-2.
    (September 30), according to real-time statistics released by Johns Hopkins University, there have been more than 33.95 million confirmed cases of new crown pneumonia worldwide, with 1.01 million deaths.
    these figures are updated daily and are expected to increase further.
    recent studies have shown that excessive inflammatory response is critical to the pathogenesis of SARS-CoV-2 and the severity of COVID-19, which can lead to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
    autopsy found that macrophages were strongly immersed in the lung tissue of patients with the deadly COVID-19.
    addition, single-cell RNA sequencing (scRNA-seq) showed a higher proportion of macrophages in bronchid alfalfa sequencing (BALF) in patients with severe COVID-19.
    , regulating excessive inflammation in SARS-CoV-2 infections for macrophages may be an effective strategy for treating PATIENT-19 patients.
    recently, researchers developed β-semi-lactose glycosidease (β-gal)-activated pre-drug SSK1, which effectively targets macrophages, where β-gal is reported to be expressed as a physiological response to immune stimuli.
    researchers found that SSK1 was effective in reducing the number of macrophages and their immersion in mouse models with lung injury, accompanied by a significant decrease in inflammation.
    these results, the researchers believe SSK1 is a promising new drug that can be used to target macrophages and treat patients with excessive inflammation in COVID-19.
    study looked at the therapeutic effects of SSK1 in non-human primate models infected with SARS-CoV-2.
    the study showed that the small molecule SSK1 effectively treated COVID-19 pneumonia by controlling macrophage immersion to reduce inflammation.
    SSK1 effectively alleviated clinical symptoms, reduced the pathological pneumonia of SARS-CoV-2 infection, and reduced macrophage immersion in lungs in animals treated with SSK1.
    results show that SSK1 has broad therapeutic potential in the treatment of pneumonia and excessive inflammation of SARS-CoV-2 infection.
    the study also found that SSK1 reduced cytokine levels in the extraterroral blood of older monkeys.
    , targeting macrophages through SSK1 may be a promising strategy for controlling inflammation in COVID-19 therapy.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.